The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Synergy Satellite: Interchangeability of biologicals in the EU – the science, practice, ethics and cost side? (supported by an educational grant from Roche)
Affiliation
Erasmus University Medical Center Rotterdam
Country
The Netherlands
1. Current Status, Position
Prof. Dr. Vulto (PharmD PhD) is hospital pharmacist, Deputy Head of the Department and Professor of Hospital Pharmacy & Practical Therapeuticsat the Erasmus University Medical Center Rotterdam.
2. Education
Arnold G. Vulto obtained his pharmacy-degree from Groningen University (The Netherlands) in 1981, with undergraduate studies in Cambridge (UK). He was trained as a pharmacologist at the Rudolf Magnus Institute for Pharmacology / Medical Faculty at the University of Utrecht and at the Karolinska Institute (Stockholm, Sweden). He specialised in hospital pharmacy at the University Hospital Maastricht, The Netherlands (1988) and obtained his PhD from Utrecht University.
3. Research Area
Professor Vulto is the (co)author of more than 130 peer reviewed papers in international journals on a wide variety of topics, all around medicines and has been supervising 15 PhD-projects. In 2010, he was elected as a Fellow of the American College of Clinical Pharmacology (FCP). In 2010 – 2011 he was a visiting scientist at the Paul Ehrlich Institute for Vaccines & Biomedicines in Langen, Germany. His current research is in the area of ATMP’s (cell- and gene therapy) and off-patent medicines (generics and biosimilars).
4. Conflict of interest: Prof. Dr. Vulto serves in the advisory board of AbbVie, Biogen and Hospira, is part of the speakers bureau for Amgen and Roche, is a speaker for Biogen, Hospira, Sandoz and EGA and a consultant for Hospira and Mundipharma.